Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Inclusion Criteria: * Adults ≥ 18 years of age * Approval from the patient's primary inpatient service * Hospitalized * Fever, documented in electronic medical record and defined as: T ≥ 38 degrees C by any conventional clinical method (forehead, tympanic, oral, axillary, rectal) * Positive test for active SARS-CoV-2 infection * Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography (CT) * Ability to provide written informed consent on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative). Exclusion Criteria: * Concurrent use of invasive mechanical ventilation * Concurrent use of vasopressor or inotropic medications * Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor in the year prior. * Known history of hypersensitivity to tocilizumab. * Diagnosis of end-stage liver disease or listed for liver transplant. * Elevation of AST or ALT in excess of 10 times the upper limit of normal. * Neutropenia (Absolute neutrophil count \< 500/uL). * Thrombocytopenia (Platelets \< 50,000/uL). * On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following: * Acalabrutinib * Ibrutinib * Zanubrutinib * On active therapy with a JAK2-targeted agent, which include the following: * Tofacitinib * Baricitinib * Upadacitinib * Ruxolitinib * Any of the following biologic immunosuppressive agent (and any biosimilar versions…